AZD1208

• UNSPSC Description:

  AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor[1].

• Target Antigen:

  Apoptosis; Autophagy; Pim

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;JAK/STAT Signaling

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/AZD1208.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(NC/1=O)SC1=C/C2=C(N3C[C@H](N)CCC3)C(C4=CC=CC=C4)=CC=C2

• Molecular Weight:

  379.48

• References & Citations:

  [1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604.|[2]Kreuz S, et al. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol Cancer. 2015 Dec 8;14:205.|[3]Harada M, et al. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10;6(35):37930-47.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 1

• CAS Number:

  1204144-28-4